These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 5839434)

  • 1. [Transitory retinopathy caused by prolonged treatment with hydroxychloroquine sulfate].
    Chiari JJ; Freyberg RH
    Arch Med Panamenos; 1965 Apr; 14(1):23-32. PubMed ID: 5839434
    [No Abstract]   [Full Text] [Related]  

  • 2. Ophthalmologic monitoring for antimalarial toxicity.
    Sfikakis PP; Mavrikakis M
    J Rheumatol; 2004 May; 31(5):1011-2; author reply 1012. PubMed ID: 15124272
    [No Abstract]   [Full Text] [Related]  

  • 3. [Eye toxicity of antimalarial agents].
    Graña Gil J; Cabana Vázquez M; Vázquez González A; Sánchez Meizoso MO
    An Med Interna; 2002 Apr; 19(4):189-91. PubMed ID: 12090061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydroxychloroquine and chloroquine: assessing the risk of retinal toxicity.
    Aylward JM
    J Am Optom Assoc; 1993 Nov; 64(11):787-97. PubMed ID: 8120333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discontinuation of antimalarial drugs in systemic lupus erythematosus.
    Wang C; Fortin PR; Li Y; Panaritis T; Gans M; Esdaile JM
    J Rheumatol; 1999 Apr; 26(4):808-15. PubMed ID: 10229401
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel method for screening the multifocal electroretonogram in patients using hydroxychloroquine.
    Chang WH; Katz BJ; Warner JE; Vitale AT; Creel D; Digre KB
    Retina; 2008; 28(10):1478-86. PubMed ID: 18997610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Statistical results of 700 electrophysiologic tests (ERG) in patients without ophthalmologic manifestations treated with synthetic antimalarials for rheumatologic or dermatologic disease].
    Rigaudière F; Pizzato M; Albuisson E; Le Gargasson JF; Grall Y
    Ophtalmologie; 1990; 4(3):254-9. PubMed ID: 2250958
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antimalarial's retinopaty remains a current threat].
    Chiffoleau A; Guillet A; Zanlonghi X; Jolliet P
    Presse Med; 2009 Apr; 38(4):662-3. PubMed ID: 19135848
    [No Abstract]   [Full Text] [Related]  

  • 9. Hydroxychloroquine in pregnant patients with systemic lupus erythematosus.
    Parke A; West B
    J Rheumatol; 1996 Oct; 23(10):1715-8. PubMed ID: 8895146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progression of hydroxychloroquine retinopathy after discontinuation of therapy: case report.
    Wei LC; Chen SN; Ho CL; Kuo YH; Ho JD
    Chang Gung Med J; 2001 May; 24(5):329-34. PubMed ID: 11480331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ocular damage in chloroquine therapy.
    Nylander U
    Acta Ophthalmol (Copenh); 1967; ():Suppl 92:1-71. PubMed ID: 4866642
    [No Abstract]   [Full Text] [Related]  

  • 12. Antimalarial drug-induced aquagenic-type pruritus in patients with lupus.
    Jiménez-Alonso J; Tercedor J; Jáimez L; García-Lora E
    Arthritis Rheum; 1998 Apr; 41(4):744-5. PubMed ID: 9550488
    [No Abstract]   [Full Text] [Related]  

  • 13. Fatal antimalarial-induced cardiomyopathy: report of 2 cases.
    Azimian M; Gultekin SH; Hata JL; Atkinson JB; Ely KA; Fuchs HA; Mobley BC
    J Clin Rheumatol; 2012 Oct; 18(7):363-6. PubMed ID: 23047537
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Ocular changes caused by long-lasting use of chloroquine and its derivatives in rheumatoid disease].
    Drewnowska-Sochańska A; Kuprianowicz W; Petrus B
    Klin Oczna; 1970; 40(4):499-503. PubMed ID: 5453064
    [No Abstract]   [Full Text] [Related]  

  • 15. Hydroxychloroquine at the recommended dose (< or = 6.5 mg/kg/day) is safe for the retina in patients with rheumatoid arthritis and systemic lupus erythematosus.
    Marmor MF
    Clin Exp Rheumatol; 2004; 22(2):143-4. PubMed ID: 15083878
    [No Abstract]   [Full Text] [Related]  

  • 16. A Critical Review of the Effects of Hydroxychloroquine and Chloroquine on the Eye.
    Costedoat-Chalumeau N; Dunogué B; Leroux G; Morel N; Jallouli M; Le Guern V; Piette JC; Brézin AP; Melles RB; Marmor MF
    Clin Rev Allergy Immunol; 2015 Dec; 49(3):317-26. PubMed ID: 25672591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular side effects of chloroquine in patients with rheumatoid arthritis, systemic lupus erythematosus and scleroderma.
    Leecharoen S; Wangkaew S; Louthrenoo W
    J Med Assoc Thai; 2007 Jan; 90(1):52-8. PubMed ID: 17621733
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current practices for monitoring ocular toxicity related to hydroxychloroquine (Plaquenil) therapy.
    Mazzuca SA; Yung R; Brandt KD; Yee RD; Katz BP
    J Rheumatol; 1994 Jan; 21(1):59-63. PubMed ID: 8151589
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Evaluation of a practical use of synthetic antimalarials in the treatment of rheumatoid polyarthritis].
    David-Chaussé J; David-Chaussé F; Picot C; Laporte G; Lagoarde J; Dehais J
    Rev Rhum Mal Osteoartic; 1971 Nov; 38(11):681-90. PubMed ID: 5151168
    [No Abstract]   [Full Text] [Related]  

  • 20. Despite hydroxyl/chloroquine's negative reputation, it may still be used by rheumatic patients in Africa.
    Cooper RG
    Tanzan J Health Res; 2008 Oct; 10(4):267-9. PubMed ID: 19402589
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.